These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 37243127)

  • 41. Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy.
    Shamsi A; Mohammad T; Anwar S; AlAjmi MF; Hussain A; Rehman MT; Islam A; Hassan MI
    Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32441299
    [TBL] [Abstract][Full Text] [Related]  

  • 42. SARS-CoV-2 Proteins: Are They Useful as Targets for COVID-19 Drugs and Vaccines?
    Mohammed MEA
    Curr Mol Med; 2022; 22(1):50-66. PubMed ID: 33622224
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
    Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
    J Virol; 2021 Oct; 95(21):e0097521. PubMed ID: 34406858
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discovery and mechanism of action of Thonzonium bromide from an FDA-approved drug library with potent and broad-spectrum inhibitory activity against main proteases of human coronaviruses.
    Wang R; Zhai G; Zhu G; Wang M; Gong X; Zhang W; Ge G; Chen H; Chen L
    Bioorg Chem; 2023 Jan; 130():106264. PubMed ID: 36395603
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ensemble-based screening of natural products and FDA-approved drugs identified potent inhibitors of SARS-CoV-2 that work with two distinct mechanisms.
    Shadrack DM; Deogratias G; Kiruri LW; Swai HS; Vianney JM; Nyandoro SS
    J Mol Graph Model; 2021 Jun; 105():107871. PubMed ID: 33684603
    [TBL] [Abstract][Full Text] [Related]  

  • 46. IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.
    Hahn F; Wangen C; Häge S; Peter AS; Dobler G; Hurst B; Julander J; Fuchs J; Ruzsics Z; Überla K; Jäck HM; Ptak R; Muehler A; Gröppel M; Vitt D; Peelen E; Kohlhof H; Marschall M
    Viruses; 2020 Dec; 12(12):. PubMed ID: 33291455
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Insights into SARS-CoV-2: Medicinal Chemistry Approaches to Combat Its Structural and Functional Biology.
    Zhuo LS; Wang MS; Yang JF; Xu HC; Huang W; Shang LQ; Yang GF
    Top Curr Chem (Cham); 2021 Apr; 379(3):23. PubMed ID: 33886017
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors.
    Sisk JM; Frieman MB; Machamer CE
    J Gen Virol; 2018 May; 99(5):619-630. PubMed ID: 29557770
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Screening of Severe Acute Respiratory Syndrome Coronavirus 2 RNA-Dependent RNA Polymerase Inhibitors Using Computational Approach.
    Dhankhar P; Dalal V; Kumar V
    J Comput Biol; 2021 Dec; 28(12):1228-1247. PubMed ID: 34847746
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.
    Báez-Santos YM; St John SE; Mesecar AD
    Antiviral Res; 2015 Mar; 115():21-38. PubMed ID: 25554382
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The lysosome: A potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications.
    Ballout RA; Sviridov D; Bukrinsky MI; Remaley AT
    FASEB J; 2020 Jun; 34(6):7253-7264. PubMed ID: 32367579
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.
    Eleftheriou P; Amanatidou D; Petrou A; Geronikaki A
    Molecules; 2020 May; 25(11):. PubMed ID: 32485894
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication.
    Chu J; Xing C; Du Y; Duan T; Liu S; Zhang P; Cheng C; Henley J; Liu X; Qian C; Yin B; Wang HY; Wang RF
    Nat Metab; 2021 Nov; 3(11):1466-1475. PubMed ID: 34580494
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Identification of Anti-Severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Oxysterol Derivatives In Vitro.
    Ohashi H; Wang F; Stappenbeck F; Tsuchimoto K; Kobayashi C; Saso W; Kataoka M; Yamasaki M; Kuramochi K; Muramatsu M; Suzuki T; Sureau C; Takeda M; Wakita T; Parhami F; Watashi K
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33808940
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV.
    Stukalov A; Girault V; Grass V; Karayel O; Bergant V; Urban C; Haas DA; Huang Y; Oubraham L; Wang A; Hamad MS; Piras A; Hansen FM; Tanzer MC; Paron I; Zinzula L; Engleitner T; Reinecke M; Lavacca TM; Ehmann R; Wölfel R; Jores J; Kuster B; Protzer U; Rad R; Ziebuhr J; Thiel V; Scaturro P; Mann M; Pichlmair A
    Nature; 2021 Jun; 594(7862):246-252. PubMed ID: 33845483
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332.
    Li J; Lin C; Zhou X; Zhong F; Zeng P; Yang Y; Zhang Y; Yu B; Fan X; McCormick PJ; Fu R; Fu Y; Jiang H; Zhang J
    J Virol; 2022 Apr; 96(8):e0201321. PubMed ID: 35389231
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection.
    Krishna G; Pillai VS; Veettil MV
    Eur J Pharmacol; 2020 Oct; 885():173450. PubMed ID: 32739174
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19.
    Rohilla S
    Drug Dev Res; 2021 Feb; 82(1):12-26. PubMed ID: 33216381
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Screening a Library of FDA-Approved and Bioactive Compounds for Antiviral Activity against SARS-CoV-2.
    Biering SB; Van Dis E; Wehri E; Yamashiro LH; Nguyenla X; Dugast-Darzacq C; Graham TGW; Stroumza JR; Golovkine GR; Roberts AW; Fines DM; Spradlin JN; Ward CC; Bajaj T; Dovala D; Schulze-Gamen U; Bajaj R; Fox DM; Ott M; Murthy N; Nomura DK; Schaletzky J; Stanley SA
    ACS Infect Dis; 2021 Aug; 7(8):2337-2351. PubMed ID: 34129317
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Knowledge-based structural models of SARS-CoV-2 proteins and their complexes with potential drugs.
    Hijikata A; Shionyu-Mitsuyama C; Nakae S; Shionyu M; Ota M; Kanaya S; Shirai T
    FEBS Lett; 2020 Jun; 594(12):1960-1973. PubMed ID: 32379896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.